Compare DFIN & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFIN | BHVN |
|---|---|---|
| Founded | 1983 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | N/A | 2017 |
| Metric | DFIN | BHVN |
|---|---|---|
| Price | $46.34 | $11.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 16 |
| Target Price | ★ $63.50 | $29.79 |
| AVG Volume (30 Days) | 272.4K | ★ 3.1M |
| Earning Date | 10-29-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.12 | N/A |
| Revenue | ★ $750,800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.20 | $2,219.74 |
| P/E Ratio | $40.84 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $37.80 | $7.48 |
| 52 Week High | $69.93 | $44.28 |
| Indicator | DFIN | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 47.77 | 53.84 |
| Support Level | $44.10 | $10.69 |
| Resistance Level | $46.60 | $11.80 |
| Average True Range (ATR) | 1.37 | 0.75 |
| MACD | 0.01 | 0.32 |
| Stochastic Oscillator | 41.10 | 82.92 |
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.